Core Insights - Rockwell Medical reported a quarterly loss of $0.05 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.04, and a decline from earnings of $0.05 per share a year ago [1][2] - The company's revenues for the quarter ended September 2025 were $15.93 million, missing the Zacks Consensus Estimate by 5.2% and down from $28.32 million year-over-year [3] - Rockwell Medical shares have decreased by approximately 48.5% since the beginning of the year, contrasting with a 16.4% gain in the S&P 500 [4] Financial Performance - The earnings surprise for the quarter was -25.00%, and the company has not surpassed consensus EPS estimates in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $18.13 million, and for the current fiscal year, it is -$0.17 on revenues of $69.91 million [8] Industry Context - Rockwell Medical operates within the Zacks Medical - Products industry, which is currently ranked in the bottom 33% of over 250 Zacks industries [9] - The performance of the stock may be influenced by the overall outlook for the industry, as top-ranked industries tend to outperform lower-ranked ones significantly [9] Future Outlook - The estimate revisions trend for Rockwell Medical was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [7] - The upcoming earnings call will be crucial for understanding management's commentary and future earnings expectations [4][5]

分组1 - ICU Medical reported quarterly earnings of $2.03 per share, exceeding the Zacks Consensus Estimate of $1.54 per share, and showing an increase from $1.59 per share a year ago, resulting in an earnings surprise of +31.82% [1] - The company achieved revenues of $533.3 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.66%, although this represents a decline from year-ago revenues of $580.07 million [2] - Over the last four quarters, ICU Medical has consistently surpassed consensus EPS and revenue estimates [2] 分组2 - The stock has underperformed, losing about 17.9% since the beginning of the year, compared to the S&P 500's gain of 15.6% [3] - The current consensus EPS estimate for the upcoming quarter is $1.66 on revenues of $527.85 million, and for the current fiscal year, it is $7.03 on revenues of $2.19 billion [7] - The Zacks Industry Rank indicates that the Medical - Products sector is currently in the bottom 40% of over 250 Zacks industries, which may negatively impact stock performance [8]

biote Corp. (BTMD) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.33 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +340.00%. A quarter ago, it was expected that this company would post earnings of $0.06 per share when it actually produced earnings of $0.1, delivering a surprise of +66.67%.Over the last four quarters, the company ha ...

Core Insights - Myomo, Inc. reported a quarterly loss of $0.11 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.03 per share a year ago [1] - The company achieved revenues of $9.65 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 6.42%, and up from $7.52 million year-over-year [2] - Myomo shares have declined approximately 71.6% year-to-date, contrasting with the S&P 500's gain of 8.6% [3] Financial Performance - The company has surpassed consensus EPS estimates two times over the last four quarters [1] - Myomo has topped consensus revenue estimates four times in the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.04 on revenues of $12.83 million, and -$0.16 on revenues of $50.34 million for the current fiscal year [7] Market Outlook - The Zacks Rank for Myomo is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] - The outlook for the Medical - Products industry, to which Myomo belongs, is currently in the bottom 38% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The correlation between near-term stock movements and earnings estimate revisions is emphasized, indicating that investors should monitor these trends closely [5]

Company Performance - Zimmer Biomet reported quarterly earnings of $2.07 per share, exceeding the Zacks Consensus Estimate of $1.98 per share, and showing an increase from $2.01 per share a year ago, resulting in an earnings surprise of +4.55% [1] - The company posted revenues of $2.08 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.59%, and an increase from $1.94 billion year-over-year [2] - Over the last four quarters, Zimmer has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Performance and Outlook - Zimmer shares have declined approximately 13.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the upcoming quarter is $1.81 on revenues of $2 billion, and for the current fiscal year, it is $7.95 on revenues of $8.19 billion [7] Industry Context - The Medical - Products industry, to which Zimmer belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

Company Overview - TriSalus Life Sciences, Inc. (TLSI) shares increased by 6.6% to close at $5.49, with trading volume significantly higher than usual, reflecting a 10.5% gain over the past four weeks [1][2] Financial Performance - The company reported a 44% year-over-year revenue growth in Q4 and a 59% growth for the full year 2024, primarily driven by the TriNav Infusion System [2] - Expected sales growth for 2025 is projected to exceed 50%, with gross margins anticipated to surpass 87% and a pathway to positive EBITDA and cash flow in the second half of 2025 [2] Market Sentiment - Investor sentiment is bolstered by the commercial launch of TriNav LV, expansion through the DELIVER program, and a strong cash position supported by anticipated funding from OrbiMed [2] - The consensus EPS estimate for the upcoming quarter is a loss of $0.20 per share, reflecting a year-over-year change of +63%, with revenues expected to reach $9.26 million, up 43.4% from the previous year [3] Earnings Estimates - Over the last 30 days, the consensus EPS estimate for TriSalus has been revised 2% lower, indicating a negative trend in earnings estimate revisions, which typically does not correlate with price appreciation [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a cautious outlook [4] Industry Comparison - TriSalus operates within the Zacks Medical - Products industry, where Abbott (ABT) has a Zacks Rank of 2 (Buy) and reported a 0.7% decline in its last trading session [4][5]

Financial Data and Key Metrics Changes - TriSalus achieved $29.4 million in net sales for 2024, reflecting a 59.4% growth over 2023, marking it as one of the fastest-growing med tech companies [12][27] - Revenue for Q4 2024 reached $8.3 million, representing a 44% increase compared to Q4 2023 and a 12% sequential increase from Q3 2024 [27] - Operating losses for Q4 2024 totaled $7.6 million, compared to losses of $14.2 million in Q4 2023, with year-to-date losses in 2024 amounting to $36.2 million compared to $54.5 million in 2023 [32] Business Line Data and Key Metrics Changes - The number of unique ordering accounts increased by 43% year-over-year from 199 to 284, with account utilization improving as average units sold per ordering account rose 10% from 12.3 to 13.5 units [13][14] - The launch of the TriNav LD infusion system and TriGuide guiding catheter expanded the PEDD portfolio, optimizing therapeutic delivery and improving procedural efficiency [18] Market Data and Key Metrics Changes - TriSalus captured 9% of the liver, TACE, and TARE procedures market in 2024, with 103 new hospital accounts opened year-to-date [28] - The PROTECT registry study is evaluating TriNav for non-malignant thyroid goiters and nodules, representing a market of approximately 50,000 annual procedures and a $400 million incremental opportunity [15] Company Strategy and Development Direction - The company prioritized its pressure-enabled drug delivery technology, aiming for EBITDA positivity by mid-2025 and cash flow positivity by year-end 2025 [10][22] - Strategic partnerships are being sought to advance the nelitolimod program in uveal melanoma liver metastases, with a focus on expanding reimbursement for radioembolization mapping [19][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving over 50% revenue growth in 2025, alongside positive full-year EBITDA and cash flow in the second half of 2025 [22][29] - The company aims to deepen penetration in the complex liver embolization market and enhance health economic and outcome research data [21][23] Other Important Information - TriSalus secured up to $50 million in debt financing from OrbiMed to support growth initiatives, with $35 million accessed to date [20] - The company filed a Form 12b-25 notification of late filing with the SEC due to errors identified in stock-based compensation and clinical trial-related R&D expenses [25][26] Q&A Session Summary Question: Where is the uptake for the launch of TriNav large vessels? - Management noted that TriNav is primarily being used in TARE more than TACE, particularly for larger vessel applications [36][38] Question: Can you provide insight on current mapping with TARE? - Management confirmed that the new CMS code allows for mapping and treatment in Medicare patients, which opens up about 25% of the market [41][46] Question: What should be expected in the PERIO-03 data? - Management clarified that the Phase I study is not to be compared to systemic chemotherapy, focusing instead on the technology's safety and efficacy [49][50] Question: Can you provide more color on account openings? - Management indicated a deliberate strategy to focus on driving utilization in existing accounts rather than aggressively opening new ones [63][65] Question: What is the attachment rate of mapping cases today in commercial? - Management believes the attachment rate is close to one-to-one on the commercial side, as mapping with the same technology yields better outcomes [80][81] Question: What is the status of the 10-K filing delay? - Management is working through the audit process and is hopeful that the numbers will not change significantly [90][92]

Core Insights - TriSalus Life Sciences, Inc. reported a quarterly loss of $0.35 per share, consistent with the Zacks Consensus Estimate, and an improvement from a loss of $1.56 per share a year ago [1] - The company generated revenues of $8.26 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 1.24% and up from $5.72 million year-over-year [2] - The stock has increased approximately 11.4% since the beginning of the year, contrasting with a -2.9% decline in the S&P 500 [3] Financial Performance - The company has not surpassed consensus EPS estimates over the last four quarters [1] - Current consensus EPS estimate for the upcoming quarter is -$0.22 on revenues of $9.4 million, and for the current fiscal year, it is -$0.60 on revenues of $44.55 million [7] Industry Context - The Medical - Products industry, to which TriSalus belongs, is currently ranked in the bottom 31% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact investor sentiment [5] Future Outlook - The sustainability of the stock's price movement will largely depend on management's commentary during the earnings call [3] - The estimate revisions trend for TriSalus is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]

Table of Contents As filed with the U.S. Securities and Exchange Commission on June 14, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) | Delaware | 3841 | 85-3009869 | | --- | --- | --- | | (State or other jurisdiction of | (Primary Standard Industrial | (I.R.S. Employer | | incorporation or organization) | Cl ...

FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Table of Contents As filed with the U.S. Securities and Exchange Commission on December 15, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Mary Szela Chief Executive Officer 6272 W. 91st Ave. Westminster, Colorado 80031 (888) 321-5212 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copy to: TRISALUS LIFE SCIENCES, INC. (Exact name of regis ...